Imagine a future where a simple saliva test at home warns you about a failing heart-long before hospital visits or invasive procedures. That future may be closer than we think. Cutting-edge research from labs across the world is building the foundation for a non‑invasive, low-cost way to screen for heart failure using saliva.
The rise of saliva-based diagnosis
Traditionally, heart failure is monitored through blood tests-especially by measuring NT-proBNP, a peptide released by the heart when it's under stress. But blood sampling requires clinics, trained personnel, and lab infrastructure. Scientists are increasingly realizing that saliva, a biofluid most of us carry in our mouths at any given moment, might offer a remarkably accessible alternative.
A systematic review published in
PubMed Centralin 2021, which pooled data from 15 studies, identified 18 different salivary biomarkers associated with heart failure.
Notably, many of these markers, such as natriuretic peptides, inflammatory cytokines, and proteins associated with tissue remodeling, are more greatly increased in the saliva of heart failure patients compared to healthy individuals. This underlines the potential of saliva as a window into cardiac health.
Pioneering research from Australia
One of the most promising efforts comes from
Griffith University and Queensland University of Technology,Australia, under the leadership of biotechnologist Professor Chamindie Punyadeera.
In a landmark 2012
study, researchersled by Punyadeera's team from Griffith University demonstrated that NT-proBNP could be reliably measured in saliva.
Their custom research showed a sensitivity of 82 % and specificity of 100 % for differential diagnosis between heart failure patients and healthy controls. Subsequently, one group employed multiprotein profiling using mass spectrometry and identified a salivary protein panel that is significantly different between patients with heart failure and healthy individuals.
Out of nearly 800 proteins analyzed, four were refined into a panel that detected early-stage heart failure with a sensitivity of about 83%.
In 2019, another study by Punyadeera's team was published for diagnosing systolic heart failure. They identified a three-protein panel, including S100-A7 and Cathelicidin, that could distinguish patients with about 81.6% diagnostic accuracy.
Importantly, salivary Galectin-3 is a protein linked to the processes of inflammation and fibrosis that may have prognostic value: in a study of more than 100 patients, higher levels of this biomarker in saliva correlated with greater risk of hospitalization or cardiovascular death, as published in
PubMed central research.From Lab to living room
In a major stride toward the practical use of saliva testing, Colorado State University researchers--led by chemist Charles Henry and graduate student Trey Pittman--collaborated on building a point-of-care device that ordinary people can use at home with Punyadeera's group at Griffith University.
The result is a prototype called eCaDI, short for electrochemical capillary-driven immunoassay. Here’s how it works:
A drop of saliva is loaded into a tiny inlet.
Fluid wicks through the microchannels because of capillary action.
Reagent pads impregnated with antibodies detect two biomarkers: Galectin-3 and S100A7.
Screen-printed electrodes at the bottom sense the proteins electrochemically, and their voltages correlate with biomarker concentration. It performed reliably for clinically relevant biomarker levels in early laboratory tests with spiked human saliva. The underlying science was described in a detailed study published in the journal Theranostics.
In 2025, researchers from QUT's ARC Centre of Excellence in Synthetic Biology reported the following breakthrough: a biosensor that selectively detects S100A7 in saliva using synthetic biology methods.
In the pilot testing, the sensor results agreed with standard diagnostics about 81 percent of the time in patients, which is strong proof of a concept for noninvasive and accessible screening.
This matters now, because:
Accessibility: Traditional tests for heart failure require a blood draw and lab infrastructure. A saliva-based test could democratize monitoring where resources are scarce, or among people struggling to access healthcare.
Early Warning: Symptoms of heart failure often emerge slowly and subtly. A home test could catch warning signs earlier, giving doctors and patients more time to act.
Because the collection of saliva is non-invasive, inexpensive, and rapid, individuals could frequently do these tests and may track trends more frequently, even over weeks or months, instead of just once at a lab. Equity: The Colorado State team believes its eCaDI device could be especially useful to rural and underserved populations where regular blood testing is a challenge.
In short, saliva testing is no longer just a scientific novelty; it's becoming a powerful, patient-friendly frontier. If these innovations make it through clinical testing and regulation, they could change how we catch and manage heart failure forever.
Follow Us On Social Media